Sign in

You're signed outSign in or to get full access.

Ashley

Managing Director and Senior Research Analyst at Piper Sandler

Ashley Lee is a Managing Director and Senior Research Analyst at Piper Sandler, specializing in the consumer and retail sectors with a focus on specialty retail, apparel, and footwear companies. She covers specific firms including Deckers Outdoor, Skechers, Crocs, Designer Brands, and Genesco, boasting a strong performance track record with a 68% success rate on TipRanks, an average return of 22.3% per rating, and ranking in the top 5% of analysts overall. Lee joined Piper Sandler in 2021 after spending over a decade at firms like William Blair and Sidoti & Company, where she honed her expertise in consumer discretionary stocks since starting her career in 2008. She holds Series 7, 63, and 86/87 FINRA licenses, underscoring her professional credentials in equity research.

Ashley's questions to Akebia Therapeutics (AKBA) leadership

Question · Q4 2025

Ashley asked for expectations regarding the R&D Day on April 2nd, including what investors should look forward to and the level of detail planned for pipeline discussions.

Answer

President, CEO, and Director John Butler explained that the R&D Day will focus on praliciguat and AKB-097, featuring key opinion leaders (KMEs) to discuss the excitement around AKB-097 as a 'next-generation complement inhibitor.' He noted the event will provide in-depth information on the preclinical data supporting decisions for praliciguat in FSGS and introduce AKB-9090, the first product from Akebia's internal discovery efforts. John Butler stated the goal is to help investors understand the rare kidney pipeline and Akebia's capabilities in expanding the HIF pipeline, building on the success of the Vafseo launch.

Ask follow-up questions

Fintool

Fintool can predict Akebia Therapeutics logo AKBA's earnings beat/miss a week before the call